DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children

Information source: University of Cincinnati
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Attention Deficit Disorder With Hyperactivity

Intervention: clonidine (Drug); methylphenidate (Drug); placebo (Other)

Phase: Phase 3

Status: Completed

Sponsored by: University of Cincinnati

Official(s) and/or principal investigator(s):
Floyd R. Sallee, M.D., Ph.D., Principal Investigator, Affiliation: Children's Hospital & Medical Center


The purpose of this study is to determine the safety and efficacy of clonidine alone or in combination with methylphenidate for children 7-12 years of age with attention-deficit, hyperactivity disorder.

Clinical Details

Official title: Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) Treatment (CAT)

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Efficacy outcome was change in score on the Conners Abbreviated Symptom Questionnaire for Teachers (ASQ-T)

Secondary outcome: the ASQ-Parent (ASQ-P) and Child Global Assessment Scales (C-GAS). Adverse events were monitored using AE logs, the Pittsburgh Side Effects Rating Scale, vital signs and electrocardiograms

Detailed description: This trial will compare the benefits and side effects of two medications-clonidine and methylphenidate (MPH)-used alone or in combination to treat ADHD in children. MPH is FDA-approved for the treatment of ADHD symptoms in children, and clonidine is FDA-approved for the treatment of hypertension in adults. Stimulant medications such as MPH are known to be safe and effective for the treatment of many ADHD symptoms. Such medicines, however, do not cure the condition or improve all of the symptoms of ADHD, and the long-term effectiveness of these medications is not well-known. In this study the participants will be randomly selected to receive one of four treatments: 1.) clonidine; 2.) MPH; 3.) clonidine and MPH; or 4.) a placebo (which is not an active medication, but a substance that is thought to have no biological effect). The time participation in the study is 16 weeks.


Minimum age: 7 Years. Maximum age: 12 Years. Gender(s): Both.


Inclusion Criteria:

- Children aged 7 through 12 in school.

- All subjects must meet DSM IV criteria for the diagnosis of ADHD of any subtype [21].

- Each subject must also satisfy the following criteria regarding the severity of ADHD

symptoms: 1. ADHD must be viewed as clinically significant and worthy of treatment by medications as judged by the parent and the site investigator. Operationally, medication treatment will be considered indicated for any subject who has ADHD symptoms that significantly interfere with academic or social functioning and that have not improved (or are not expected to improve) sufficiently with non-pharmacological interventions (e. g., modifying the classroom environment, tutoring). 2. The site investigator's rating of global functioning on the C-GAS must yield a score of 70 or below. Scores below 70 on the C-GAS are designated as indicating abnormal function [22]. The score of 70 corresponds to the anchor point description: "Some difficulty in a single area, but generally functioning pretty well."

- Screen of Intelligence using the vocabulary and block design subtests of the Wechsler

Intelligence Scale for Children-Third Edition indicates an estimated I. Q > 70.

- Informed consent/assent signed. We will not enroll any child who does not want to


- The designated school for each subject agrees to participate in the study by

completing all required questionnaires and following all specified procedures.

- The child must be able to swallow the tablets and capsules used in this study.

Exclusion Criteria:

- Subjects with tic disorder of any type or tic symptoms, a primary diagnosis of major

depression, pervasive developmental disorder, autism, any psychotic disorder, and mental retardation (based on current DSM criteria) will be excluded. We will not exclude subjects with obsessive-compulsive disorder, oppositional-defiant disorder or conduct disorder.

- The presence of a known medical condition that would preclude the use of MPH or


- Known pregnancy. A urinary pregnancy test will be performed for all menstruating

female subjects. Female subjects of child bearing potential will be advised not to become pregnant. In this circumstance, study medication will be tapered and discontinued and the subject will be terminated from the study. A urinary pregnancy test will be repeated at the end of the study. Subjects who request information regarding possible birth control mechanisms will be referred to their primary care physicians.

- Known presence of impaired renal function. A routine urinalysis will be performed

for each subject to exclude signs of renal failure.

- Known active cardiovascular disease/anomaly, which would be a contraindication for

the use of MPH or clonidine.

- Subjects may not receive any other medication for the treatment of ADHD. Treatment

with MPH or other stimulants must be discontinued for at least 2 weeks prior to enrollment and treatment with other medications to treat ADHD (e. g., antidepressants, clonidine) must be discontinued for at least 6 weeks prior to enrollment.

- Subjects may not receive any other psychotropic medication (e. g., serotonin reuptake

inhibitors), anxiolytics (e. g., clonazepam) or hypnotics. Any such medication must be discontinued at least 6 weeks prior to enrollment.

- Previous use of MPH or clonidine will be permitted.

Locations and Contacts

SUNY Buffalo, Center For Children & Families, Buffalo, New York 14214, United States

University of Rochester, Department of Neurology, Rochester, New York 14642, United States

Children's Hospital Medical Center, Cincinnati, Ohio 45229, United States

Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States

Additional Information

Starting date: September 1999
Last updated: May 20, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017